Home > Insider Trading > Filing (0001144204-13-031153)

Filing Details

Accession Number:: 0001144204-13-031153
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-05-22 18:30:28
Reporting Period:: 2013-05-20

Filing Date:: 2013-05-22
Accepted Time:: 2013-05-22 18:30:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1235007	Endocyte Inc	ECYT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1286338	Ann Hanham	One Embracadero Ctr Ste 2700 San Francisco CA 94111		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2013-05-20	11,633	$14.42	685,705	No	4	S	Indirect	By Burrill Life Sciences Capital Fund, L.P.
Common Stock	Disposition	2013-05-21	10,155	$14.31	675,550	No	4	S	Indirect	By Burrill Life Sciences Capital Fund, L.P.
Common Stock	Disposition	2013-05-22	15,141	$14.39	660,409	No	4	S	Indirect	By Burrill Life Sciences Capital Fund, L.P.
Common Stock	Disposition	2013-05-20	967	$14.42	57,030	No	4	S	Indirect	By Burrill Indiana Life Sciences Capital Fund, L.P.
Common Stock	Disposition	2013-05-21	845	$14.31	56,185	No	4	S	Indirect	By Burrill Indiana Life Sciences Capital Fund, L.P.
Common Stock	Disposition	2013-05-22	1,259	$14.39	54,926	No	4	S	Indirect	By Burrill Indiana Life Sciences Capital Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Burrill Life Sciences Capital Fund, L.P.
No	4	S	Indirect	By Burrill Life Sciences Capital Fund, L.P.
No	4	S	Indirect	By Burrill Life Sciences Capital Fund, L.P.
No	4	S	Indirect	By Burrill Indiana Life Sciences Capital Fund, L.P.
No	4	S	Indirect	By Burrill Indiana Life Sciences Capital Fund, L.P.
No	4	S	Indirect	By Burrill Indiana Life Sciences Capital Fund, L.P.

Footnotes

Represents the sale of 12,600 shares in multiple transactions, ranging in price from $14.40 to $14.51 per share, resulting in a weighted average sale price per share of $14.42. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
Ann Hanham is a managing member of Burrill & Company (Life Science GP), LLC which has the ultimate voting and investment power over shares held of record by Burrill Life Sciences Capital Fund, L.P., and she may be deemed to have voting and investment power over shares held of record by Burrill Life Sciences Capital Fund, L.P. Ms. Hanham disclaims beneficial ownership of the shares directly held by the entities affiliated with Burrill & Company except to the extent of her individual pecuniary interest therein.
Represents the sale of 11,000 shares in multiple transactions, ranging in price from $14.25 to $14.39 per share, resulting in a weighted average sale price per share of $14.31. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
Ann Hanham is a managing member of Burrill & Company (Indiana GP), LLC which has the ultimate voting and investment power over shares held of record by Burrill Indiana Life Sciences Capital Fund, L.P., and she may be deemed to have voting and investment power over shares held of record by Burrill Indiana Life Sciences Capital Fund, L.P. Ms. Hanham disclaims beneficial ownership of the shares directly held by the entities affiliated with Burrill & Company except to the extent of her individual pecuniary interest therein.
Represents the sale of 16,400 shares in multiple transactions, ranging in price from $14.30 to $14.44 per share, resulting in a weighted average sale price per share of $14.39. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.